ZEOX
Zeo ScientifiX, Inc.Company Information
- Company Name
- Zeo ScientifiX, Inc.
- CIK
- CIK0001557376
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- ZEOX: OTC
- Fiscal Year End
- October 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- ZEOX
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-06-25
- Last sale
- 2023-12-19
- Shares purchased (TTM)
- 81,377
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2022-12-31
- Institutional shares owned
- 280,000
- Shares outstanding
- 7,009,549
- Ownership
- 3.99%
Earnings Market Reaction
- Filing date
- 2026-06-15
- Price on filing date
- —
- 1-month reaction
- 23.53%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-04-30 | 2026-01-31 | 2025-10-31 | 2025-07-31 | 2025-04-30 | 2025-01-31 | 2024-10-31 | 2024-07-31 | 2024-04-30 | 2024-01-31 | 2023-10-31 | 2023-07-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash | 2 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | ||||||
| Other Receivables Net Current | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Assets Current | 3 | 2 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 1 | ||||||
| Prepaid Expense Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | ||||||
| Other Assets | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Security Deposit | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Deposits Assets Noncurrent | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Assets | 4 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Accounts Payable And Accrued Liabilities Current | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | ||||||
| Finance Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Liabilities Current | ||||||||||||||||||
| Liabilities Current | 3 | 3 | 3 | 4 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | ||||||
| Operating Lease Liability Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Contractual Obligation | - | - | - | - | - | - | - | - | - | - | - | 0 | ||||||
| Convertible Notes Payable Current | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Deferred Revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | ||||||
| Liabilities | 3 | 3 | 3 | 4 | 4 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Additional Paid In Capital | 69 | 68 | 66 | 65 | 63 | 62 | 61 | 60 | 58 | 57 | 56 | 54 | ||||||
Stockholders Equity | ||||||||||||||||||
| Stockholders Equity | 1 | -0 | -1 | -2 | -2 | -2 | -2 | -1 | -2 | -2 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -69 | -69 | -68 | -67 | -65 | -63 | -62 | -61 | -60 | -59 | -58 | -56 | ||||||
| Finance Lease Liability Noncurrent | - | - | - | - | - | - | - | - | - | - | 0 | - | ||||||
| Liabilities And Stockholders Equity | 4 | 3 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | ||||||
| Long Term Debt | - | - | - | - | - | - | - | 0 | 0 | 0 | - | - | ||||||
| Debt Instrument Unamortized Discount | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | - | 0 | - | ||||||
| Preferred Stock Par Or Stated Value Per Share | - | - | 0.00 | - | - | - | 0.00 | - | - | - | 0.00 | - | ||||||
| Preferred Stock Shares Authorized | - | - | 10 | - | - | - | 10 | - | - | - | 10 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | 2,500 | ||||||
| Common Stock Shares Issued | 8 | 8 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 6 | 7 | 7 | ||||||
| Shares Outstanding | 8 | 8 | 7 | 7 | 6 | 6 | 6 | 7 | 6 | 6 | 7 | 7 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialZeo ScientifiX, Inc. (ZEOX) — SEC Financial Statements & Analysis
Zeo ScientifiX, Inc. (ZEOX) is a biological products, (no diagnostic substances) company, incorporated in NV. Zeo ScientifiX, Inc. trades on OTC as: ZEOX. Zeo ScientifiX, Inc. (ZEOX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-04-30, filed with the SEC on 2026-06-15. Based on that filing, Zeo ScientifiX, Inc. carries a market cap of $15.05M, a P/E ratio of -3.87x, a P/B ratio of 21.14x, a P/S ratio of 2.15x, an enterprise value of $13.48M, and an EV/EBITDA multiple of -3.33x. On profitability, it posts a gross margin of 81.52%, an operating margin of -59.10%, a net margin of -55.59%, a Return on Equity (ROE) of 559.65%, and a Return on Assets (ROA) of -145.99%. Per share, it reports EPS of $-0.50, diluted EPS of $-0.50, free cash flow per share of $-0.17, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 52.75% year-over-year, net income growth of -20.73% year-over-year, and EPS growth of -35.17% year-over-year. On the balance sheet, it maintains a current ratio of 1.05x, a quick ratio of 0.68x, working capital of $155.00K, a debt-to-equity ratio of 4.46x, a debt ratio of 0.82, an interest coverage ratio of -54.33x, free cash flow of $-1.35M (TTM), and net debt of $-1.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $15.05M
- P/E TTM
- -3.87x
- EPS TTM
- $-0.50
- P/B TTM
- 21.14x
- ROE TTM
- 559.65%
- ROA TTM
- -145.99%
- Debt To Equity
- 4.46x
- Free Cash Flow TTM
- $-1.35M
- Net Revenue TTM Growth 1Y
- 52.75%
Data as of 2026-04-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Zeo ScientifiX, Inc. in?
Zeo ScientifiX, Inc. (ZEOX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does ZEOX trade on?
Zeo ScientifiX, Inc. (ZEOX) trades on the OTC.
Where is Zeo ScientifiX, Inc. incorporated?
Zeo ScientifiX, Inc. is incorporated in NV.
When was Zeo ScientifiX, Inc. (ZEOX)'s most recent SEC filing?
Zeo ScientifiX, Inc. (ZEOX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-04-30, filed with the SEC on 2026-06-15.
What is ZEOX's market cap?
Zeo ScientifiX, Inc. (ZEOX) has a market capitalization of $15.05M as of 2026-04-30.
What is ZEOX's EPS (earnings per share)?
Zeo ScientifiX, Inc. (ZEOX)'s trailing twelve month EPS is $-0.50 as of 2026-04-30.
What is ZEOX's ROE (return on equity)?
Zeo ScientifiX, Inc. (ZEOX)'s trailing twelve month Return on Equity (ROE) is 559.65% as of 2026-04-30.
What is ZEOX's ROA (return on assets)?
Zeo ScientifiX, Inc. (ZEOX)'s trailing twelve month Return on Assets (ROA) is -145.99% as of 2026-04-30.
What is ZEOX's EV/EBITDA?
Zeo ScientifiX, Inc. (ZEOX)'s trailing twelve month EV/EBITDA is -3.33x as of 2026-04-30.